PTC Therapeutics PTCT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's EPS (diluted)?
- PTC Therapeutics (PTCT) reported EPS (diluted) of -$0.03 in Q1 2026.
- How has PTC Therapeutics's EPS (diluted) changed year-over-year?
- PTC Therapeutics's EPS (diluted) decreased by 100.3% year-over-year, from $10.04 to -$0.03.
- What is the long-term trend for PTC Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2024), PTC Therapeutics's EPS (diluted) has grown at a -13.9% compound annual growth rate (CAGR), from -$7.42 to -$4.73.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.